General MedicationsINHALATIONStandard
YUTREPIA
TREPROSTINIL SODIUM
Standard Dose
EQ 0.0265MG BASE/INH
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview YUTREPIA is listed in Drugs@FDA under application 213005 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TREPROSTINIL SODIUM Form and strength POWDER;INHALATION - EQ 0.0265MG BASE/INH Sponsor LIQUIDIA TECH Submission history Latest submission status date: 2025-05-23 00:00:00.
Structured Monograph
Clinical summary
Approval overview YUTREPIA is listed in Drugs@FDA under application 213005 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TREPROSTINIL SODIUM Form and strength POWDER;INHALATION - EQ 0.0265MG BASE/INH Sponsor LIQUIDIA TECH Submission history Latest submission status date: 2025-05-23 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.